JW Pharmaceutical Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From JW Pharmaceutical Corporation
Two Korean Pharmas Vie For Wins In High-Need Gout Space
Based on promising Phase II data, two companies in South Korea are moving ahead with late-stage development in the gout space, with JW Pharmaceutical getting approvals to begin a multinational Phase III trial for epaminurad, while LG Chem has recently submitted an application for a Phase III program with its contender tigulixostat.
More Cell, Gene Therapy Firms Benefit From Korea R&D Grants
An analysis of the Korea Drug Development Fund’s selection of projects for R&D grants so far this year shows more applications and particular support for domestic cell and gene therapy projects, reflecting the strong interest in this area globally.
China Rush Over? Korean Firms Step Up To Seize Opportunities
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.
Korea Expands Financial Support For Global Innovation Bid
While keeping its policy focus mainly on controlling the pandemic situation, South Korea is also increasing R&D grants to support the development of innovative drugs with global blockbuster potential through the launch of renewed and better funded Korea Drug Development Fund.
- Generic Drugs
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- C&C Research Laboratories
- Choongwae Pharma Corporation
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.